Melbourne, Australia – Starpharma Holdings Ltd (ASX:SPL; OTCQX:SPHRY) has announced that Chief Executive Officer Dr Jackie Fairley will present at the Canaccord Genuity 33^rd Annual Growth Conference in Boston on August 14.

The event brings together around 200 companies from diversified industry sectors, and selected from around the world based on their high growth potential. Hundreds of sophisticated investors have registered to attend the premier North American investor conference.

As part of the conference Dr Fairley will also meet with US fund managers and investors to continue to expand awareness of Starpharma and its dendrimer platform amongst international audiences.

 “We are very pleased to be invited to present as part of this important international conference which focuses on companies operating in fast growing innovation industries,” Dr Fairley said.

“Starpharma has a diverse international shareholder register, with around a third of our investors based outside of Australia, and our technologies are highly relevant to US and broader international audiences.”

“This is a great opportunity to raise awareness of Starpharma and its products with US investors.”

The presentation will provide a brief overview of the company and will include:

• Starpharma’s lead product VivaGel^® for the management of bacterial vaginosis
       including plans for phase three clinical trials for prevention of recurrent BV;
• An overview of the attractive commercial opportunity for the VivaGel^®-coated condom
       licensed to Ansell and Okamoto and currently under regulatory review ahead of
       market launch;
• The Company’s dendrimer-docetaxel formulation due to enter the clinic later this year
       and Starpharma’s broader drug delivery program; and
• Starpharma’s internal and partnered agrochemical program.

Download ASX Announcement: Starpharma to present at Canaccord Genuity Annual Growth Conference ( pdf file, 1MB)